How to properly combine topical Pyrilutamide (KX-826) and Minoxidil? Timing question.
    2/20/2026

    From the encyclopedia
    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    Pyrilutamide →

    highly targeted anti-androgen that might have minimal systemic effects

    At a glance
    In this question or advice post, the primary subjects mentioned are
    💧 Minoxidil (topical)
    the tone is 😐 neutral.

    Other terms

    Combining topical minoxidil and pyrilutamide (KX-826) for hair loss treatment. It is suggested to apply minoxidil first, wait 20 minutes, then apply pyrilutamide for better absorption.
    View this post in the Community →

    Similar Community Posts Join

    6 / 6 results

      community Optimal Pyrilutamide (KX-826) Mix and application

       9 upvotes 3 years ago
      The conversation discusses how to mix pyrilutamide for hair loss treatment, suggesting a mixture of 500mg pyrilutamide with 70% ethanol and 30% propylene glycol, and a potential application dose of 1mL. The user has not personally used pyrilutamide but has researched its preparation and application based on others' experiences.

      community PYRILUTAMIDE KX-826 experience

       99 upvotes 4 years ago
      A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.

      community Kintor’s KX-826 Pyrilutamide!!

       152 upvotes 4 years ago
      KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

      community Any treatment not nuking systemic DHT levels?

       16 upvotes 6 months ago
      Hair loss treatments that avoid significantly lowering systemic DHT levels, focusing on topical options like dutasteride mesotherapy, minoxidil, and ketoconazole. The user is exploring alternatives like KX-826 and RU58841 due to concerns about hormone levels.

    Related Research

    6 / 6 results
      Androgenetic Alopecia: Therapy Update

      research Androgenetic Alopecia: Therapy Update

      May 2023 in “Drugs”
      This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
      Development and Validation of Androgen-Induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents

      research Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents

      1 citations , April 2024 in “Journal of Pharmaceutical and Pharmacological Sciences”
      This study evaluated androgen-induced hair loss and anagen induction mouse models, finding that Minoxidil and Pyrilutamide significantly promoted hair growth by decreasing androgen receptor protein levels and enhancing the Wnt/β-Catenin signaling pathway, supporting their use in studying novel treatments for androgenetic alopecia.
      Recent Advances in Drug Development for Hair Loss

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
      The 100 Most Cited Articles in Androgenetic Alopecia: A Bibliometric Analysis

      research The 100 most cited articles in androgenetic alopecia: A bibliometric analysis

      March 2025 in “Medicine”
      This study performed a bibliometric analysis of the 100 most cited articles on androgenetic alopecia from 1975 to 2024, revealing that U.S. authors contributed most and highlighting a trend toward research focused on treatment options, especially between 2020 and 2024.